key: cord-0706128-ek7gkrnl authors: Naseer, Faiza; Ahmad, Tahir; Gul, Rabia; Anjum, Sadia title: Serendipity for the intervention of COVID-19 and prostatic adenocarcinoma (PaC) date: 2022-03-10 journal: Prostate Cancer Prostatic Dis DOI: 10.1038/s41391-022-00502-z sha: 25ad33efaeb10f7dd84c38281f2b961d10845da7 doc_id: 706128 cord_uid: ek7gkrnl nan range 11-18 days of symptoms). Among deceased cases, 64.9% had at least one comorbidity related to high BP, hyperglycemia, and cardiovascular and/or respiratory illness and concluded that men were associated with worse outcomes regardless of age and COVID-19 with preexisting comorbidities. This higher incidence and severity can be associated with shorter life expectancy in men vs women worldwide [7] . A review article published in Communication Biology reporting gender-based discrimination of COVID-19 and higher risk in PaC. It supported the gender-based disproportion, i.e., 2.8:1.7% male:female mortality rate in China and in France, Germany, Iran, Italy, South Korea, England, and America [8] . The researcher reported 58% deaths in men and 42% in women as of June 2020 and 60.3% of hospitalized patients were male and 66.5% of men were over 20 years old. It concluded that chemotherapy causes systemic immunosuppression and make patients more prone to viral infections. A cohort study was conducted from March to December 2020 and compared the severity of COVID-19 in prostate cancer, gastrointestinal cancer, breast cancer, and solid cancers. This study reported higher hospitalizations and death among PaC compared to other malignancies [9] . The interaction of angiotensin-converting enzyme 2 (ACE2) receptor, transmembrane serine proteases II (TMPRSS2), and another protein furin protease with the SARS-CoV-2 spike glycoprotein plays an important role in virus entry and are the ideal points of attack for the development of medical approaches and novel treatments. TMPRSS2 are widely recognized as a critical host cell factor involved in the pathogenesis of variety of cancer and viral infections, including influenza A viruses and SARS-CoV coronaviruses. TMPRSS2 was first identified for its role in prostate cancer pathogenesis following the discovery of its oncogenic fusion gene with ETS transcription factor such as ETS related genes (ERG). TMPRSS-ERG protein is overexpressed in local and metastatic tumors. Downregulating these proteins is one of the strategies used to treat prostate cancer. TMPRSS2, along with its oncogenic potential in PaC, also facilitates cellular entry of the respiratory syndrome viruses. SARS-CoV2 enters the cell by binding to the ACE2 receptor on alveolar epithelial cells, then TMPRSS2 cleaves S-glycoprotein of the coronavirus, resulting in viral fusion with cell membranes. Camostat mesylate and nafamostat are protease inhibitors employed to study the role [10] . TMPRSS2 inhibitors and antiandrogens serve as potential drug targets for the treatment of PaC and COVID-19. Several clinical studies have been developed to evaluate the effectiveness of such inhibitors as a therapeutic option in COVID-19 (Table 1) . Developing novel strategies to combat SARS-CoV-2 is an emerging need in this era of pandemic. Evidence from preclinical studies suggested that TMPRSS2 expression can be modified by suppressing ARs to treat SARS-CoV-2 infection. Previous retrospective clinical studies examining the potential of androgen antagonists in COVID-19 and PaC have drawn controversial results due to the small sample size. Detailed observational studies are required to develop evidence of the beneficial use and safety profile of androgen antagonists prior to clinical use. Advanced therapeutic options for treatment of metastatic castration resistant prostatic adenocarcinoma. Front Pharmacol Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries Clinical characteristics of coronavirus disease 2019 in China Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a singlecentered, retrospective, observational study Positive rate of RT-PCR detection of SARS-CoV-2 infection in 4880 cases from one hospital in Gender differences in patients with COVID-19: focus on severity and mortality. Front Public health Higher severity and mortality in male patients with COVID-19 independent of age and susceptibility. medRxiv Increased hospitalization and mortality from COVID-19 in prostate cancer patients Crosstalk between COVID-19 and prostate cancer FN: conceptualization and writing. TA: review and supervision. RG: drafting and writing. SA: review and proofreading. The authors declare no competing interests. Correspondence and requests for materials should be addressed to Faiza Naseer or Tahir Ahmad. Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.